GPS Wealth Strategies Group LLC bought a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,000 shares of the biopharmaceutical company’s stock, valued at approximately $54,000.
A number of other large investors also recently modified their holdings of ITCI. Amalgamated Bank increased its holdings in Intra-Cellular Therapies by 1.4% in the 4th quarter. Amalgamated Bank now owns 15,036 shares of the biopharmaceutical company’s stock valued at $796,000 after acquiring an additional 213 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its holdings in shares of Intra-Cellular Therapies by 4.0% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,745 shares of the biopharmaceutical company’s stock worth $304,000 after buying an additional 223 shares during the last quarter. Metropolitan Life Insurance Co NY increased its holdings in shares of Intra-Cellular Therapies by 4.0% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 5,745 shares of the biopharmaceutical company’s stock worth $304,000 after buying an additional 223 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Intra-Cellular Therapies by 14.4% in the 4th quarter. Exchange Traded Concepts LLC now owns 2,687 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 339 shares during the last quarter. Finally, Profund Advisors LLC increased its holdings in shares of Intra-Cellular Therapies by 6.4% in the 4th quarter. Profund Advisors LLC now owns 8,203 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 492 shares during the last quarter. Hedge funds and other institutional investors own 85.70% of the company’s stock.
Intra-Cellular Therapies Stock Performance
Shares of ITCI opened at $63.32 on Friday. The company has a 50 day moving average price of $63.08 and a 200-day moving average price of $55.00. Intra-Cellular Therapies, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $67.05. The stock has a market capitalization of $6.07 billion, a PE ratio of -26.38 and a beta of 1.13.
Insider Buying and Selling
In related news, Director Nostrand Robert L. Van sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $63.00, for a total transaction of $630,000.00. Following the completion of the transaction, the director now owns 9,345 shares in the company, valued at approximately $588,735. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 81,854 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $63.97, for a total transaction of $5,236,200.38. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Nostrand Robert L. Van sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $63.00, for a total transaction of $630,000.00. Following the transaction, the director now owns 9,345 shares in the company, valued at approximately $588,735. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
A number of analysts have recently weighed in on the stock. UBS Group boosted their target price on shares of Intra-Cellular Therapies from $74.00 to $80.00 in a report on Friday. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price target on shares of Intra-Cellular Therapies in a report on Tuesday, April 18th. Bank of America upped their price target on shares of Intra-Cellular Therapies from $62.00 to $63.00 and gave the company a “buy” rating in a report on Wednesday, March 29th. Cantor Fitzgerald upped their price target on shares of Intra-Cellular Therapies from $87.00 to $90.00 in a report on Friday, May 5th. Finally, JPMorgan Chase & Co. upped their price target on shares of Intra-Cellular Therapies from $58.00 to $62.00 in a report on Monday, June 5th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Intra-Cellular Therapies has an average rating of “Moderate Buy” and an average target price of $75.27.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Featured Stories
- Five stocks we like better than Intra-Cellular Therapies
- MarketBeat Week in Review – 6/26 – 6/30
- Tesla: Can Downgrades Make Sense After A 170% Rally?
- Buffett’s Berkshire Increases Stake In Occidental Petroleum (OXY)
- Rally Gains Momentum On Soft PCE Data
- Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?
Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
